Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Uterine Cervical Neoplasms 2Nasopharyngeal Carcinoma 2Stomach Neoplasms 1Pancreatic Cancer Resectable 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Locally Advanced Gastric Cancer 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

camrelizumab 2S 1 (combination) 2Oxaliplatin 2apatinib 1Taxes 1Hyperthermic Intraperitoneal Chemotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Locally Advanced Gastric Cancer × Taxes × Clear all
NCT05524974 2022-09-01

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Fujian Medical University

Phase 2 Not yet recruiting
203 enrolled
Gastrointestinal

Locally Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡